| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2011 | WO2011019617A2 Vitamin d3 and analogs thereof for treating alopecia |
| 02/17/2011 | WO2011019616A1 Boron-containing small molecules as antiprotozoal agents |
| 02/17/2011 | WO2011019612A1 Boron-containing small molecules as antiprotozoal agents |
| 02/17/2011 | WO2011019538A1 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| 02/17/2011 | WO2011019498A1 Inhibition of glycerol-3-phosphate acyltransferase (gpat) and associated enzymes for treatment of viral infections |
| 02/17/2011 | WO2011019419A1 Carbohydrate-mediated tumor targeting |
| 02/17/2011 | WO2011019413A1 Pharmaceutical composition and administrations thereof |
| 02/17/2011 | WO2011019410A1 Ophthalmic drug delivery system containing phospholipid and cholesterol |
| 02/17/2011 | WO2011019405A1 Pyrimidine compounds as tuberculosis inhibitors |
| 02/17/2011 | WO2011019400A2 Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity |
| 02/17/2011 | WO2011019393A2 Class- and isoform-specific hdac inhibitors and uses thereof |
| 02/17/2011 | WO2011019348A1 CREATINE β-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
| 02/17/2011 | WO2011019323A1 Particulate hyaluronic acid formulations for cellular delivery of bioactive agents |
| 02/17/2011 | WO2011019317A1 Compositions and methods for treating fungal infection of the nail |
| 02/17/2011 | WO2011019124A1 Agmatine as an agent for enhancing stem cell efficacy |
| 02/17/2011 | WO2011019090A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| 02/17/2011 | WO2011019089A1 Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| 02/17/2011 | WO2011019074A1 Nucleic acid that controls fibrosis of cells or organs |
| 02/17/2011 | WO2011019065A1 Tumor angiogenesis inhibitor |
| 02/17/2011 | WO2011019060A1 Hedgehog signal inhibitor |
| 02/17/2011 | WO2011019045A1 Disintegrating particle composition and orally rapidly disintegrating tablet |
| 02/17/2011 | WO2011019043A1 Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles |
| 02/17/2011 | WO2011018902A1 Pharmaceutical composition for suppressing pain |
| 02/17/2011 | WO2011018896A1 Production method for astaxanthin-containing composition |
| 02/17/2011 | WO2011018894A1 Pyrrolopyrimidine derivatives as potassium channel modulators |
| 02/17/2011 | WO2011018763A1 Combination of proantocycidins such as pycnogenol or grape seeds and centella asiatica for the treatment of cardiovascular disorders such as atherosclerosis |
| 02/17/2011 | WO2011018742A1 Triazine derivates for use in the treatment of malaria |
| 02/17/2011 | WO2011018672A1 Methods and substances for stimulating muscle regeneration |
| 02/17/2011 | WO2011018653A2 Treatment of viral infections |
| 02/17/2011 | WO2011018588A2 Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
| 02/17/2011 | WO2011018587A2 Fgf receptor-activating n-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof |
| 02/17/2011 | WO2011018582A2 Floating microgranules |
| 02/17/2011 | WO2011018532A2 Steroid solvates |
| 02/17/2011 | WO2011018531A1 Dry powder inhaler formulations |
| 02/17/2011 | WO2011018522A1 Storage-stable formulation of paracetamol in aqueous solution |
| 02/17/2011 | WO2011018510A1 New macrolides and their use |
| 02/17/2011 | WO2011018506A1 miRNA COMPOUNDS FOR TREATMENT OF PROSTATE CARCINOMA |
| 02/17/2011 | WO2011018495A1 New compounds for the treatment of cns disorders |
| 02/17/2011 | WO2011018488A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 02/17/2011 | WO2011018487A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 02/17/2011 | WO2011018482A1 Stabilised particles comprising 5-methyl-(6s)-tetrahydrofolate |
| 02/17/2011 | WO2011018480A1 Pharmaceutical composition including a dha ester to be parenterally administered |
| 02/17/2011 | WO2011018474A1 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
| 02/17/2011 | WO2011018454A1 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| 02/17/2011 | WO2011018417A1 Inhibitors of jnk |
| 02/17/2011 | WO2011018225A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| 02/17/2011 | WO2011018224A1 Combination therapy of an afucosylated cd20 antibody with bendamustine |
| 02/17/2011 | WO2011018101A1 Lenalidomide salts |
| 02/17/2011 | WO2011017998A1 Gambogic acid cyclization analogues, preparation method and application thereof |
| 02/17/2011 | WO2011017909A1 Pharmaceutical solution of cetirizine hydrochloride |
| 02/17/2011 | WO2011017907A1 Azetidinone compounds and medical use thereof |
| 02/17/2011 | WO2011017905A1 Use of senkyunolide i in manufacture of medicament for anti-depression, treating migraine and other diseases related to serotonergic system |
| 02/17/2011 | WO2011017810A1 Combination therapy to treat vascular disorders |
| 02/17/2011 | WO2011017809A1 Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer |
| 02/17/2011 | WO2011017800A1 Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid |
| 02/17/2011 | WO2010146585A4 Tellurium-containing compounds for treating viral infections |
| 02/17/2011 | WO2010146078A3 Novel uses of hydroxyproline compositions |
| 02/17/2011 | WO2010145681A8 A process for preparing trichloroammineplatinate salt and the products obtained therein |
| 02/17/2011 | WO2010143074A3 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor |
| 02/17/2011 | WO2010138828A3 Potassium channel modulators |
| 02/17/2011 | WO2010134097A3 Pharmaceutical composition of olanzapine and process for their preparation |
| 02/17/2011 | WO2010127206A3 Intraocular bioactive agent delivery compositon including a molecular partitioning system |
| 02/17/2011 | WO2010124097A3 Transcription factor modulating compounds and methods of use thereof |
| 02/17/2011 | WO2010123959A3 2,5-disubstituted arylsulfonamide ccr3 antagonists |
| 02/17/2011 | WO2010123845A3 Siderophore conjugate immunogenic compositions and vaccines |
| 02/17/2011 | WO2010123599A9 Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus |
| 02/17/2011 | WO2010123527A3 Use of epidermal growth factor inhibitors in the treatment of viral infection |
| 02/17/2011 | WO2010122980A8 NOVEL THYROID HORMONE β RECEPTOR AGONIST |
| 02/17/2011 | WO2010122109A9 Method for the treatment of acute myeloid leukemia |
| 02/17/2011 | WO2010118339A3 Formulations of indole-3-carbinol derived antitumor agents with increased oral bioavailability |
| 02/17/2011 | WO2010118291A3 Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| 02/17/2011 | WO2010117979A3 Serotonin and norepinephrine reuptake inhibitor |
| 02/17/2011 | WO2010117639A9 Inhibition of prostglandin e2 receptors for the treatment of endometriosis |
| 02/17/2011 | WO2010115125A3 Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
| 02/17/2011 | WO2010092260A3 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof |
| 02/17/2011 | WO2010088409A3 Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| 02/17/2011 | WO2010087976A3 Anti-cancer protein-platinum conjugates |
| 02/17/2011 | WO2010042701A3 Corticosteroid compositions for use in treating diseases of the upper and lower airway passages |
| 02/17/2011 | WO2010014841A8 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
| 02/17/2011 | US20110041190 Novel chimeric proteins |
| 02/17/2011 | US20110040161 Device for generating a detectable signal based upon concentration of at least one substance |
| 02/17/2011 | US20110040144 Method and apparatus for weight control by olfactory nerve ablation |
| 02/17/2011 | US20110040088 Fused heterocyclic compounds |
| 02/17/2011 | US20110039946 Method of improving atopic dermatological diseases, in which a composition comprising magnolol, honokiol or a combination thereof is administered to a patient with atopic dermatological diseases |
| 02/17/2011 | US20110039945 Compositions containing resveratrol and pectin |
| 02/17/2011 | US20110039944 Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| 02/17/2011 | US20110039943 Methods for treating skin disorders with topical nitrogen mustard compositions |
| 02/17/2011 | US20110039942 Titration package |
| 02/17/2011 | US20110039940 ritonavir; treating gout or familial Mediterranean fever with side effect reduction of colchicine |
| 02/17/2011 | US20110039939 Storage-stable formulation of paracetamol in aqueous solution |
| 02/17/2011 | US20110039938 Storage-stable formulation of paracetamol in aqueous solution |
| 02/17/2011 | US20110039937 Novel process for the preparation of vorinostat |
| 02/17/2011 | US20110039936 N-Substituted Benzenepropanamide or Benzenepropenamide Derivatives for Use in the Treatment of Pain and Inflammation |
| 02/17/2011 | US20110039935 Use of pharmacologically active chemical compounds |
| 02/17/2011 | US20110039934 Process for the preparation of derivatives of 1-(2- halobiphenyl-4-yl)-cyclopropanecarboxylic acid |
| 02/17/2011 | US20110039933 S1p-1 receptor agonists |
| 02/17/2011 | US20110039932 Polyunsaturated fatty acid monovalent and divalent metal salt synthesis |
| 02/17/2011 | US20110039930 Fast-acting naproxen composition with reduced gastrointestinal effects |
| 02/17/2011 | US20110039929 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 02/17/2011 | US20110039928 Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition |